Early Predictors of Long-term Outcomes of HCV-negative Liver Transplant Recipients Having Survived the First Postoperative Year
Authors:
- 1 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (2) , 382-390
Abstract
Background The non-improvement in >1-year post-liver transplant (LT) survival and diminishing importance of hepatitis C (HCV) with modern antivirals justify identification of early factors predictive of long-term outcome post-LT in HCV-negative recipients. Methods This nationwide study included all 631 HCV-negative adult patients transplanted in Finland 1982-2013 with at least 1-year graft survival (6311 person-year follow-up). We tested 37 variables, including immunosuppression, for their association with >1-year combined graft loss/mortality, late rejection, cancer, or infections. Results Significant multivariate predictors of graft loss/mortality were male gender (HR 2.40, P = 0.001), pretransplant hepatocellular (HR 2.92, P = 0.001) or biliary cancer (HR 12.7, P < 0.001), glomerular filtration rate (HR 0.89, P = 0.002), hypertension (HR 0.44, P < 0.001), early posttransplant infections (HR 1.52-1.67, P = 0.007-0.03), and alkaline phosphatase (ALP) (HR 1.05, P < 0.001). Elevated ALP at 1 year, affecting 30% of patients, predicted both graft loss and rejection, independent of immunologic stability, etiology, and immunosuppression type. Area under the curve of ALP in predicting graft loss from rejection was 0.81 (95% CI 0.71-0.90) and 0.85 (95% CI 0.72-0.98, P = 0.001) among patients under 50. Among immunologically stable patients who underwent transplantation after 2000, antimetabolite use at 1 year was associated with improved survival (P = 0.04), specifically in the subgroup with native-liver hepatocellular or biliary cancer (P = 0.02). Conclusions Easily measurable, widely available, and noninvasive factors known at 1 year post-LT can help stratify patients according to their long-term risk of death or graft loss, and thus facilitate a personalization of long-term follow-up. ALP deserves routine monitoring, and the cause for an elevated ALP should be sought.Keywords
This publication has 37 references indexed in Scilit:
- Differences in long‐term survival among liver transplant recipients and the general population: A population‐based nordic studyHepatology, 2015
- Improving Long-Term Outcomes After Liver TransplantationClinics in Liver Disease, 2014
- Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: Past, present and futureWorld Journal of Gastroenterology, 2014
- Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)Journal of Hepatology, 2012
- Solid Organ Allograft Survival Improvement in the United States: The Long-Term Does Not Mirror the Dramatic Short-Term SuccessAmerican Journal of Transplantation, 2011
- Life expectancy of adult liver allograft recipients in the UKGut, 2006
- No Improvement in Long-Term Liver Transplant Graft Survival in the Last Decade: An Analysis of the UNOS DataAmerican Journal of Transplantation, 2006
- 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcomeThe Lancet, 2006
- A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristicsLiver Transplantation, 2003
- The association between hepatitis C infection and survival after orthotopic liver transplantationGastroenterology, 2002